Elicio Therapeutics, Inc.
ELTXHealthcare|Biotechnology|US
$1.51
+0.11 (+7.86%)
DCF Value
$0.23
Tangible Book / Share
$0.72
Cash / Share
$1.18
Clinical Trials (4)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05726864 A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors | Pancreatic Ductal Adenocarcinoma, Colorectal Cancer | P1P2 | Active | 158 | RCT, Open-label | ELI-002 7P |
| NCT07671339 A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer | Pancreatic Cancer | P1 | Recruiting | 20 | RCT, Open-label | ELI-002 7P, Tislelizumab, mFOLFIRINOX |
| NCT04853017 A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors | Minimal Residual Disease, KRAS G12D | P1 | Completed | 25 | Open-label | ELI-002 2P |
| NCT07083479 Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma | Pancreatic Ductal Adenocarcinoma, KRAS G12D | NO_LONGER_AVAILABLE | — | — | ELI-002 7P |